This article is available to subscribers. Subscribe now. Already have an account? Sign in

Original ArticleFree PreviewArchive

Pertussis Vaccine — An Analysis of Benefits, Risks and Costs

List of authors.
  • Jeffrey P. Koplan, M.D., M.P.H.,
  • Stephen C. Schoenbaum, M.D., M.P.H.,
  • Milton C. Weinstein, Ph.D.,
  • and David W. Fraser, M.D.

Abstract

Using decision analysis, we estimated the benefits, risks and costs of routine childhood immunization against pertussis. Without an immunization program, we predict that there would be a 71-fold increase in cases and an almost fourfold increase in deaths (2.0 to 7.6) per cohort of one million children. With a vaccination program, we predict 0.1 case of encephalitis associated with pertussis and five cases of post-vaccination encephalitis; without a program, there would be only 2.3 cases of encephalitis associated with pertussis. Community vaccination would reduce by 61 per cent the costs related to pertussis. Our analysis supports continuation of vaccination in routine childhood immunization programs, but suggests the need for more reliable data on complications from the vaccine, further study of the epidemiology of pertussis and development of a less toxic vaccine. (N Engl J Med 301:906–911, 1979)

Funding and Disclosures

We are indebted to Dr. Nicholas Fiumara for information on reported cases of pertussis in Massachusetts and to Mr. Norman Staehling, Mr. Paul Stange and Dr. Andrew Sumner for assistance.

Author Affiliations

From the Office of Program Planning and Evaluation and the Bureau of Epidemiology, Center for Disease Control, Atlanta, the Department of Medicine, Peter Bent Brigham Hospital and Harvard Medical School and the Harvard School of Public Health, Boston, and the John F. Kennedy School of Government, Cambridge, MA (address reprint requests to Dr. Koplan at the Office of Program Planning and Evaluation, Center for Disease Control, Atlanta, GA 30333).

Print Subscriber? Activate your online access.